These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 19917313)

  • 1. AID-mediated somatic hypermutation for generation of viral envelope protein diversity in patient-specific therapeutic HIV vaccines based on induction of neutralizing antibodies.
    Suslov KV
    Immunol Lett; 2010 Jan; 128(1):86-7. PubMed ID: 19917313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines.
    Evans TG; Frey S; Israel H; Chiu J; El-Habib R; Gilbert P; Gaitan A; Montefiori DC;
    Vaccine; 2004 Jun; 22(20):2626-30. PubMed ID: 15193388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AIDS/HIV. A boost for HIV vaccine design.
    Burton DR; Weiss RA
    Science; 2010 Aug; 329(5993):770-3. PubMed ID: 20705840
    [No Abstract]   [Full Text] [Related]  

  • 4. Genotypic and phenotypic variation of HIV-1: impact on AIDS pathogenesis and vaccination.
    Wolfs TF; Nara PL; Goudsmit J
    Chem Immunol; 1993; 56():1-33. PubMed ID: 8383980
    [No Abstract]   [Full Text] [Related]  

  • 5. Importance of conformation on the neutralizing antibody response to HIV-1 gp120.
    Steimer KS; Haigwood NL
    Biotechnol Ther; 1991; 2(1-2):63-89. PubMed ID: 1726963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
    Bower JF; Green TD; Ross TM
    Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
    Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
    Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
    Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
    Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.
    Buckner C; Gines LG; Saunders CJ; Vojtech L; Srivastava I; Gettie A; Bohm R; Blanchard J; Barnett SW; Safrit JT; Stamatatos L
    Virology; 2004 Mar; 320(1):167-80. PubMed ID: 15003872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Role of the HIV-1 gp120 V1/V2 domains in the induction of neutralizing antibodies].
    Granados-González V; Piedrahita LD; Martínez M; Genin C; Riffard S; Urcuqui-Inchima S
    Enferm Infecc Microbiol Clin; 2009 Nov; 27(9):523-30. PubMed ID: 19409660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicities of Env glycoproteins from circulating HIV-1 isolates in China focusing on the strategy of "DNA prime plus protein boost".
    Wang Z; Wang SX; Liu SY; Bao ZY; Zhuang DM; Li L; Zhang CH; Zhang L; Li JY; Lu S
    Chin Med J (Engl); 2009 Oct; 122(19):2339-45. PubMed ID: 20079137
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of induction of antibodies specific for conserved, discontinuous epitopes of HIV-1 envelope glycoprotein by candidate AIDS vaccines.
    VanCott TC; Bethke FR; Burke DS; Redfield RR; Birx DL
    J Immunol; 1995 Oct; 155(8):4100-10. PubMed ID: 7561123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The antigenic structure of the HIV gp120 envelope glycoprotein.
    Wyatt R; Kwong PD; Desjardins E; Sweet RW; Robinson J; Hendrickson WA; Sodroski JG
    Nature; 1998 Jun; 393(6686):705-11. PubMed ID: 9641684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of gp120-specific protective immune responses by genetic vaccination with linear polyethylenimine-plasmid complex.
    Garzón MR; Berraondo P; Crettaz J; Ochoa L; Vera M; Lasarte JJ; Vales A; Van Rooijen N; Ruiz J; Prieto J; Zulueta J; González-Aseguinolaza G
    Vaccine; 2005 Feb; 23(11):1384-92. PubMed ID: 15661387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AIDS/HIV. Host controls of HIV neutralizing antibodies.
    Haynes BF; Verkoczy L
    Science; 2014 May; 344(6184):588-9. PubMed ID: 24812389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does AID aid AIDS?
    Suslov KV
    Immunol Lett; 2004 Jan; 91(1):1-2. PubMed ID: 14757362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human Immunodeficiency Virus Tat Protein Aids V Region Somatic Hypermutation in Human B Cells.
    Wang X; Duan Z; Yu G; Fan M; Scharff MD
    mBio; 2018 Apr; 9(2):. PubMed ID: 29666292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New frontiers of immunotherapy for HIV.
    Haynes BF
    Lancet; 1996 Dec; 348(9041):1531-2. PubMed ID: 8950876
    [No Abstract]   [Full Text] [Related]  

  • 20. What Are the Primary Limitations in B-Cell Affinity Maturation, and How Much Affinity Maturation Can We Drive with Vaccination? Lessons from the Antibody Response to HIV-1.
    Victora GD; Mouquet H
    Cold Spring Harb Perspect Biol; 2018 May; 10(5):. PubMed ID: 28630079
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.